基于网络药理学对麦卡辛 (KCHO-1) 作为阿尔茨海默氏病中神经炎症通路的多目标调节器的表征

相关实验视频

Updated: Jan 13, 2026

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

Hyein Jo¹, Joonyoung Shin¹, Hyorin Lee¹

¹Institute for Global Rare Disease Network, Professional Graduate School of Korean Medicine, Wonkwang University, Iksan 54538, Republic of Korea.

|January 10, 2026

概括

梅卡辛是一种草药配方,通过与神经免疫通路相互作用,可能针对阿尔茨海默病 (AD). 这项网络药理学研究确定了核心基因和潜在由Mecasin生物活性化合物调节的途径.

科学领域:

草药是一种草药.
网络药理学网络药理学
阿尔茨海默氏症疾病研究研究

背景情况:

梅卡辛 (KCHO-1) 是一种标准化的多草药配方,含有多种生物活性化合物.
它与阿尔茨海默病 (AD) 分子网络的潜在相互作用需要调查.

研究的目的:

探索Mecasin在阿尔茨海默病中的分子机制,使用整合性网络药理学方法.
为了确定潜在的核心目标和途径调节的Mecasin相关的AD病原体.

主要方法:

对Mecasin的生物活性成分及其标进行选.
与AD相关的基因交叉引用目标.
网络分析包括蛋白质-蛋白质相互作用,基因本体学和KEGG通路丰富.
分子对接用于机械验证.

主要成果:

鉴定了6个核心基因 (AKT1,STAT3,IL6,TNF,EGFR,IL1B) 参与神经元生存,炎症和压力路径.
梅卡辛化合物通过分子对接显示出与AKT1和TNF等点的潜在相互作用.
网络集成揭示了Mecasin与相互连接的神经免疫通路的交互潜力.

结论:

梅卡辛通过其植物化学物质可以调节与阿尔茨海默病相关的多个相互连接的神经免疫通路.
这些in silico发现为了解Mecasin潜在的治疗机制提供了系统层面的框架.
进一步的实验验证是有必要的,以证实这些潜在的AD多目标机制.

关键词:

阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.凯格 (KEGG) 是一个机器人中的机器人分子对接的分子对接.网络药理学网络药理学

更多相关视频

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)

Published on: January 10, 2025

相关概念视频

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.

Ligand-Gated Ion Channel Receptor: Gating Mechanism

Ligand-Gated Ion Channel Receptor: Gating Mechanism

Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...

Cholinergic Receptors: Muscarinic

Cholinergic Receptors: Muscarinic

The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine.
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

MAPK Signaling Cascades

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...